Continuing Education

2017 Conference Continuing Education

The Community Oncology Conference is pleased to partner with Imedex to offer continuing medical education (CME), Maintenance of Certification (MOC), and other professional credits to attendees. See below and stay tuned for more on how to submit documentation such as evaluations and certificates of attendance.


This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Imedex and Community Oncology Alliance. Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

Imedex, LLC designates this enduring activity for a maximum of 13.25 AMA PRA Category 1 CreditsTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Maintenance of Certification

Successful completion of this CME activity enables a participant to earn up to 13.25 MOC points towards the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is Imedex’s responsibility to submit participant completion information to ACCME for granting ABIM MOC Points.


This activity has been submitted to the Oncology Nursing Society (ONS) for approval to award contact hours. ONS is accredited as an approver of continuing nursing education by the American Nurses Credentialing Center’s COA.

(CNE ID #A-0280) was approved by the Oncology Nursing Society, an accredited approver by the American Nurses Credentialing Center’s COA.
This activity may award up to 13.3 contact hours.

Download the Informational Document


Imedex, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This knowledge activity (0408-9999-17-001-L01-P) has been approved for a maximum of 13.25 contact hours (1.2 CEUs). To receive credit, participants must complete an activity evaluation survey.

Processing of CME

After the conference, participants will be emailed a link from the Imedex Office of CME ( with instructions regarding claiming CME or to request a certificate of participation. We will not be issuing certificates of credit or certificates of participation onsite.

Who Should Attend/Target Audience

This educational activity is designed to meet the educational needs of US-based community oncologists and other healthcare professionals (physicians, physicians-in-training, oncology nurses, nurse practitioners, pharmacists, physician assistants, etc.) involved and/or interested in the therapeutic management of patients with cancer.

Learning Objectives – Physicians & Nurses

After successfully completing this continuing medical education activity, participants should be able to

  • Identify the potential economic impact of biosimilars in cancer care
  • Evaluate recent advances and emerging data regarding new treatments for lung cancer
  • Formulate a plan to integrate emerging immune checkpoint inhibitors when available into your treatment plans for patients with genitourinary, lung, breast, or hematologic cancers
  • Describe next-generation DNA sequencing and its role in guiding treatment selection
  • Relate financial aspects of cancer care, including drug cost/value and payment and reimbursements models, to their impact on care delivery
  • Interpret the evolving political landscape of cancer care and its effects on patient care and advocacy
  • Plan strategies to advocate for patients on behalf of the community cancer care delivery team

Learning Objectives – Pharmacists

At the completion of this activity, participants will be able to:

  • Identify strategies to overcome challenges in dispensing oncology agents to cancer patients.
  • Be aware of current and proposed legislation affecting oncology pharmacy.
  • Evaluate the potential benefits of specialty pharmacy accreditation to your practice.
  • Identify the tools available to achieve pharmacy accreditation.
  • Formulate a plan to improve patients’ adherence to oral cancer drugs.


The following companies have provided an educational grant in support of this conference:

  • Astellas
  • AstraZeneca
  • Bristol-Myers Squibb
  • Celgene
  • Exelixis
  • Genomic Health
  • Lilly
  • Merck
  • Pfizer

The Commercial Exhibition

As a part of the conference, companies and organizations may display their products and services.  The exhibition is located in Potomac CD/1-6 and Potomac AC Lobby.  Exhibitions should not be construed as an endorsement of a product or manufacturer’s claims by Imedex.

The following companies are exhibitors at this conference:

Daiichi Sankyo, Inc.
Integra Connect
Adaptive Biotechnologies
American College of Surgeons
Boehringer Ingelheim
BTG International
Cota Healthcare
Cure Forward
Foundation Medicine
Genomic Health
Harborside Press
INSYS Therapeutics, Inc.
Integrated Oncology
Michael J. Hennessey Associates, Inc. (AJMC)
Miraca Life Sciences
Myriad Genetics
Navigating Cancer
Novartis- 2 bronze
Outcome Health
Patient Education Network
Patient Point
SCIO Management Soultions
Sun Pharma
Taiho Oncology
Tolmar Pharmaceuticals
Unlimited Systems
Video Seo Pro
Zyno Medical, LLC

Faculty Disclosure

As an accredited provider of continuing medical education, Imedex, LLC requires anyone in a position to affect the activity’s subject matter to disclose any financial relationships they have as related to the contents of their presentations. The existence of commercial or financial interests of presenters related to the subject matter of their presentations should not be construed as implying bias or decreasing the value of their presentations. However, disclosure should help participants form their own judgments.

All presenters were independently selected by the organizing committee. Those presenters who disclosed affiliations or financial interests with the entities who produce, market, re-sells or distributes products or services used on or by patients, to which they may refer, are listed below.

1=grant/research support 2=consultant 3=speaker’s bureau 4=stock shareholder 5=other support

Buell, Roberta Boehringer Ingelheim1,5-SPOUSE, Medicines Co1,5-SPOUSE, Pfizer1,5-SPOUSE, Sanofi1,5-SPOUSE
Carter, Buddy  
Chaudhry, Basit Tesaro4 – SPOUSE
Cox, Joshua Boehringer Ingelheim5 – SPOUSE
D’Amato, Steve Eli Lilly & Co3, Merck3, Tesaro3
George, Daniel Acceleron Pharma2,3,5, Acerta1, Astellas/Medivation1,2,3,5, Bayer H/C Pharma1,2,3,5, BioPharm2,3,5, Bristol-Myers Squibb1,2,3,5, Clovis2,3, Exelixis1,2,3,5, Genentech1,2,3,5, Innocrin/Viarmet1,2,3,5, Janssen1,2,3,5, Merck2,3,5, Millennium1, Novartis1,2,3,5, Pfizer1,2,3,5, Sanofi2,3,5
Gordan, Lucio AmerisourceBergen2, Myriad2, Guardant2, Takeda2
Jones, Ben McKesson5-Employee
Li, Edward Apobiologix, Eli Lilly & Co, Pfizer
Licitra, Edward Takeda2,3
Lynch, Joseph Millennium3, Takeda3
McCullough, Stacey AstraZeneca2, Boehringer Ingelheim2, Cardinal2, Eisai2, Exelixis2, 3, Novartis2, Pfizer2
Mortier, Jeff AmerisourceBergen2, AstraZeneca2, Genentech2, Johnson & Johnson2
Murphree, Todd Astellas3, Bayer2, Eisai3, Novartis2,3,5, Taiko2
O’Shaughnessy, Joyce AbbVie2,5, AstraZeneca2, Arno Tx2, Celgene2,5, Concept Therapeutics2, Genentech2, Eisai2, Lilly5, Nektar Therapeutics2,5, Novartis2,5, Pfizer2,5, Sandoz2,5, Zymeworks 2,5
Patel, Kashyap Janssen Oncology2,3, Heron2,3, Novartis2, Pfizer2
Patton, Jeffrey Amgen2, Astellas2, BMS2, Gilead2, Lilly2
Paulson, Steven Actinium4, Alexion2,3, Boehringer Ingelheim2,3, Celator4, Clovis4
Portell, Craig AbbVie1, Acerta1, Bristol-Myers Squibb1, Genentech/Roche1, Infinity1, TG Therapeutics1
Rahman, Alti Amgen2, Celgene2, Coherus2, Genentech2, Heron2, Tesaro2
Reynolds, Craig Boehringer Ingleheim2,3,5, Bristol-Myers Squibb2,3, Celgene2,3,5, Genentech2,3, Eli Lilly & Co2,3,5
Vacirca, Jeffrey Heron Therapeutics2,5
Whitfield, Ed Genentech2, Johnson & Johnson2, AstraZeneca2, AmerisourceBergen2
Wilfong, Lalan McKesson5-EMPLOYEE
Zon, Robin Amgen1


Imedex, LLC Staff Disclosure of Financial Relationships

All Imedex staff members who are in a position to control content of this activity have no financial relationships with any commercial interests, except for the following individuals:

               Chris Bolwell owns shares of stock of GlaxoSmithKline.

Imedex, LLC is an independent provider of continuing medical education. Imedex, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA has regulatory authority.

Unapproved and Investigational Uses of Drugs and Devices

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the Food and Drug Administration (FDA) of the United States or European Medicines Agency (EMA). Participants are encouraged to consult the EMA-approved or FDA-approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed in this document are the opinions of the presenters and do not necessarily reflect the opinions of Imedex, LLC.


The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society.

About Imedex

Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.

©1993-2017 Imedex, LLC. All rights reserved. Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.